Lanicemine

Drug Profile

Lanicemine

Alternative Names: ARL 15896; ARL 15896AR; ARR 15896; ARR 15896AR; BHV-5500; FPL 15896; FPL 15896AR

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astra Arcus USA
  • Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Epilepsy; Stroke

Most Recent Events

  • 31 May 2017 Baylor College of Medicine and National Institute of Mental Health plan a phase I trial for Depression and Post traumatic stress disorders (NCT03166501)
  • 23 Jan 2007 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
  • 17 Feb 2006 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top